GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET ANALYSIS

The Global and China Osteoporosis Drugs Market is estimated to be valued at US$ 14.6 Bn in 2023 and is expected to exhibit a CAGR of 3.9% during the forecast period (2023-2030).

Analysts’ Views on Global and China Osteoporosis Drugs Market :

Increasing number of research & development activities are expected to boost the growth of the global and China osteoporosis drugs market over the forecast period. For instance, according to evidence presented at the 13th International Conference on Osteoporosis, Arthritis, and Musculoskeletal Disorders held in Paris, France in April 2021, risedronate GR (Actonel GR) demonstrated superior outcomes for fracture risk reduction in patients with osteoporosis, compared to those who received an immediate release (IR) bisphosphonate.

Figure 1. Global and China Osteoporosis Drugs Market Share (%), by Drug Type, 2023

To learn more about this report, request sample copy

Global and China Osteoporosis Drugs Market– Driver

• Increased mergers and acquisition scenarios between key market players: The growing incidences of mergers and acquisition scenarios between key market players  are a major factor driving the growth of the market over the forecast period. For instance, in December 2022,  Amge Inc- a U.S.-based multinational biopharmaceutical company acquired Horizon Therapeutics- a developer of drugs for rare, autoimmune, and severe inflammatory disease, to expand their product portfolio and offerings.
• Increased product approvals by regulatory bodies: The increasing product approvals by regulatory bodies of respective countries can drive the growth of the global and China osteoporosis drugs market. For instance, on February 06, 2023, The U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA) for a proposed biosimilar to denosumab. Denosumab is a RANK ligand inhibitor for the treatment of postmenopausal women with osteoporosis at high risk for fracture; to increase bone mass in men with osteoporosis at high risk for fracture; for the treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture; to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer; and to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. Sandoz International GmbH (A subsidiary of Novartis AG)- a global healthcare company based in Switzerland, filed the BLA (Biologics License Applications).

Figure 2. Global and China Osteoporosis Drugs Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Global and China Osteoporosis Drugs Market - Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global and China osteoporosis drugs market over the forecast period. This is due to the increasing number of drug discovey and drug development activities in the region. For instance, on April 27, 2023, a collaborative group of scientists from Florida International University- a U.S.-based public research university, hypothesized that increasing RXFP2 activity could increase bone formation in conditions like osteoporosis.

Global and China Osteoporosis Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

• Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
• COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.
• The COVID-19 pandemic had a negative impact on the global and China osteoporosis drugs market. According to an article published in May 2021, in PubMed- a free search engine for biological databases and medical reports, stated that the screening, diagnosis and management of patients with osteoporosis proved to be challenging during the COVID-19 pandemic. The follow-up of patients to the metabolic bone clinics was disrupted which created treatment delays, particularly in patients on denosumab. The quality of osteoporosis care of patients with a new fragility fracture or hip fracture following surgery dramatically decreased during the pandemic.

Global and China Osteoporosis Drugs Market Segmentation:

The global and China osteoporosis drugs market report is segmented into drug type, route of administration , distribution channel, and region.

• By Drug Type, the market is segmented into bisphosphonates (sub-segmneted into Alderonate, Risedronate, Ibandronate, Zoledronic Acid and Others), calcitonin, hormone therapy, selective estrogen receptor modulators (serms), parathyroid hormone-related protein (pthrp) analog, and rank ligand (rankl) inhibitor. Out of which, the bisphosphonates  segment is expected to hold a dominant position in the global and China osteoporosis drugs market during the forecast period and this is because it reduce the risk of hip and spine fractures.
• By Route Of Administration, the market is segmented into oral, injectable and others. Out of which, the oral segment is expected to hold a dominant position in the global and China osteoporosis drugs market during the forecast period and this is attributed to the ease of administration of the drug for geriatric patient through this route.
• By Distribution Channel, the market is segmented into hospitals pharmacies, online pharmacies, and retail pharmacies. Out of which, the hospital segment is expected to dominate the market over the forecast period and this is attributed to the increased hospitalization of patients  due to osteoporotic surgeries.
• By Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, China, Middle East, and Africa. Out of which, the North America segment is expected to dominate the market over the forecast period and this is attributed to the increased product launches in the region.
• Among all the segmentations, the drug type segment has the highest potential due to the increasing research & development activities across the world over the forecast period. For instance, on according to the  data shared on January 03, 2023, by The American College of Physicians- a U.S.-based national organization of internists, who specialize in the diagnosis, treatment, and care of adults, new osteoporosis treatment guidelines suggest patients to stop prescription after five years as there is an increased risk of long-term harms of osteoporosis drugs when compared to its effectiveness.

Global and China Osteoporosis Drugs Market Cross Sectional Analysis:

Among route of administration, oral segment is expected to be dominant in the North America region. The research presented at various conferences can help raise awareness about osteopororsis and related treatments. For instance, on June 2023, the first clinical evidence of safe and successful delivery of the osteoporosis drug teriparatide through an oral robotic pill was presented at ENDO 2023- the Endocrine Society's annual meeting in Chicago, U.S. The robotic pill,  moves through the stomach intact, allowing maximum bioavailability and enhanced drug delivery.

Global and China Osteoporosis Drugs Market: Key Developments

•  On April 19, 2023, Zydus Group- an India-based multinational pharmaceutical company, announced that it had received approval from the United States Food and Drug Administration (USFDA) for an osteoporosis drug (Estradiol). Estradiol is an estrogenic steroid used to various indications such as postmenopausal osteoporosis and others
• On March 31, 2023, Mabwell Therapeutics, Inc.- a biotechnology company, announced that China’s National Medical Products Administration (NMPA) approved MAILISHU, a denosumab biosimilar, for the treatment of osteoporosis in postmenopausal women at high risk of fracture. MAILISHU was developed by Mabwell Therapeutics, Inc.’s subsidiary, T-Mab.
• In June 2020, researchers from School of Medicine CHA University- a private university in South Korea, reported that Tauroursodeoxycholic acid (The U.S. FDA-approved hydrophilic bile acid for the treatment of chronic cholestatic liver disease) may provide a favorable effect on bones and could be used for the prevention and treatment of osteoporosis.

Global and China Osteoporosis Drugs Market: Key Trends

• Rising Technological Advacements : Approval and launch of AI-based products to predict osteoporosis is expected to aid in growth of the market. For instance, in May 2020, Zebra Technologies Corp- a company that provide patient identity management, mobile health devices, and business intelligence data, received U.S. FDA 510(k) clearance for its Vertebral Compression Fractures product, which automatically identifies findings suggestive of compression fractures, which enables clinicians to place patients that are at risk of osteoporosis in treatment pathways.
• Adoption of Various Growth Strategies: Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, TEIJIN LIMITED- a Japan-based chemical, pharmaceutical and information technology company, partnered with Radius Health, Inc.- a global biopharmaceutical company, and submitted a New Drug Application (NDA) for abaloparatide-SC in Japan for the treatment of osteoporosis in patients who are at high risk for fractures.

Global and China Osteoporosis Drugs Market: Restraint

• Potential side effects of osteoporosis drugs: Adverse effects of osteoporosis drugs are expected to hinder growth of the market. For instance, consumption of alendronate may lead to stomach pain, acid reflux, constipation, diarrhea, upset stomach, nausea, or muscle, and joint pain. This restrain can be overcome by the immediate reporting of the adverse drug reactions (ADR) to the nearest doctor, healthcare providers or ADR monitoring centres.
• Risk of cardiac disorders: Several barriers like the cardiac risks associated with osteoporosis drugs that are restraining the growth of this market. For instance, according to an article published in July 2020, in  PubMed- a free search engine for biological databases and medical reports, Selective Estrogen Receptor Modulators (SERMs) are associated with a significantly increased risk of Venous thromboembolism (VTE) and may be associated with fatal stroke. This can be overcome by restricting the intake of the drug dose strictly as per the recommendation of the doctor. 

Global and China Osteoporosis Drugs Market- Key Players

Major players operating in the global and China osteoporosis drugs market include Merck KGaA, Lilly, Procter & Gamble, Enzo Biochem Inc., Sanofi, Novartis AG, Wyeth Nutrition (A subsidiary of Pfizer Inc.), F. Hoffmann-La Roche Ltd, GSK plc, UCB S.A., Amgen Inc., BeiGene, Inc., Bone Biologics Corp, TEIJIN LIMITED, Eden Biologics (Formerly known as JHL Biotech Inc.), Keros Therapeutics, and Taro Pharmaceutical Industries Ltd.